99 related articles for article (PubMed ID: 22019807)
1. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
[TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry.
Bader-Meunier B; Decaluwe H; Barnerias C; Gherardi R; Quartier P; Faye A; Guigonis V; Pagnier A; Brochard K; Sibilia J; Gottenberg JE; Bodemer C;
J Rheumatol; 2011 Jul; 38(7):1436-40. PubMed ID: 21677003
[TBL] [Abstract][Full Text] [Related]
7. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
[TBL] [Abstract][Full Text] [Related]
8. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia.
Wiernik PH; Adiga GU
Curr Med Res Opin; 2011 Oct; 27(10):1987-93. PubMed ID: 21905969
[TBL] [Abstract][Full Text] [Related]
9. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
10. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
11. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
13. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
Roll P; Ostermeier E; Haubitz M; Lovric S; Unger L; Holle J; Kötter I; Henes JC; Bergner R; Rubbert-Roth A; Specker C; Schulze-Koops H; Müller-Ladner U; Fleck M; Burmester GR; Hiepe F; Heitmann S; Aringer M; Fischer-Betz R; Dörner T; Tony HP
J Rheumatol; 2012 Nov; 39(11):2153-6. PubMed ID: 22984269
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
[TBL] [Abstract][Full Text] [Related]
17. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
Wilkes MR; Sereika SM; Fertig N; Lucas MR; Oddis CV
Arthritis Rheum; 2005 Aug; 52(8):2439-46. PubMed ID: 16052580
[TBL] [Abstract][Full Text] [Related]
18. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
19. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis.
Peng CH; Kuo HC
Urol Int; 2007; 78(1):78-81. PubMed ID: 17192738
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
